GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (STU:6IB) » Definitions » Shiller PE Ratio

Innovent Biologics (STU:6IB) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Shiller PE Ratio?

Innovent Biologics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Innovent Biologics Shiller PE Ratio Historical Data

The historical data trend for Innovent Biologics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Shiller PE Ratio Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial - - - - -

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovent Biologics's Shiller PE Ratio

For the Biotechnology subindustry, Innovent Biologics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Shiller PE Ratio falls into.



Innovent Biologics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Innovent Biologics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Innovent Biologics  (STU:6IB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Innovent Biologics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (STU:6IB) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (STU:6IB) Headlines

No Headlines